Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cultivated autologous limbal epithelial cells (Massachusetts Eye and Ear)
- Development stage
- Unknown
- Lead developer
- Massachusetts Eye and Ear
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
Cultivated autologous limbal epithelial cells (CALEC) is an experimental autologous cell therapy developed by Massachusetts Eye and Ear for the treatment of unilateral limbal stem cell deficiency (LSCD). The therapy involves harvesting a small biopsy of limbal stem cells from the patient's healthy contralateral eye, which are then expanded ex vivo using a novel xenobiotic-free, serum-free, and antibiotic-free manufacturing process. These expanded cells are seeded onto a de-epithelialized human amniotic membrane to create a bio-engineered cellular tissue graft. This graft is surgically transplanted onto the damaged cornea to restore the limbal stem cell population and re-establish the ocular surface integrity. Phase I/II clinical trials have demonstrated high success rates in restoring corneal surfaces in patients with chemical or thermal burns.
- Other names
- CALEC transplantationCultivated autologous limbal epithelial cell transplantation
Beyond the preview
Go deeper on cultivated autologous limbal epithelial cells (Massachusetts Eye and Ear).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cultivated autologous limbal epithelial cells (Massachusetts Eye and Ear).